BioCentury | Sep 20, 2020
Product Development

Amgen highlights durability, seeks biomarkers as response rates slip for KRAS inhibitor AMG 510

...in combination with a pan-KRAS inhibitor from Boehringer Ingelheim GmbH...
BioCentury | Sep 17, 2020
Deals

Mirati and Boehringer partner to test KRAS-KRAS combo

...G12C mutation-selective inhibitor MRTX849 from Mirati Therapeutics Inc. (NASDAQ:MRTX) in combination with BI 1701963, a SOS1:pan-KRAS inhibitor from Boehringer Ingelheim GmBH...
...Src homology protein tyrosine phosphatase 2SOS1 – Sons of sevenless homolog 1 Lauren Martz Mirati Therapeutics Inc. Amgen Inc. Boehringer Ingelheim GmbH KRAS...
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...point to therapeutic targets. Companies involved include Boehringer Ingelheim GmbH...
BioCentury | Sep 10, 2020
Finance

MiNA raises £23M in first venture round 12 years after launch

...for metabolic diseases, and is developing saRNA candidates for fibrotic diseases, including non-alcoholic steatohepatitis (NASH), with Boehringer Ingelheim GmbH...
BioCentury | Aug 22, 2020
Product Development

Europe’s five-year plan to tackle COVID-19 and other coronavirus threats

...best possible compound much faster.” Cyrille Kuhn, Boehringer Ingelheim...
...antibody discovery through development to viable therapies.For example,  Boehringer Ingelheim GmbH is...
...Co. Ltd. European Federation of Pharmaceutical Industries and Associations Boehringer Ingelheim Bill...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...and develop biomarkers for the early detection of cardiovascular disease. The round was led by Boehringer Ingelheim...
BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

...Medicine in 2018 with €8 million in seed funding from founding investors Andera Partners and Boehringer Ingelheim...
...of employees: 18 Funds raised: €74 million Investors: Versant Ventures, RA Capital Management, Andera Partners, Boehringer Ingelheim...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...countries (see “ Atogepant Phase IIb/III to Prevent Migraine ”). Jardiance reduces heart failure risk Boehringer Ingelheim GmbH...
...G12C inhibitor-unknown MRTX849 sotorasib (AMG 510) Keytruda, pembrolizumab (MK-3475, lambrolizumab) ravidasvir (ASC16, PPI-668) Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) AL001 Boehringer Ingelheim GmbH AbbVie...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...raises seed funding from BI, Evotec Quantro Therapeutics GmbH raised an undisclosed seed round from Boehringer Ingelheim GmbH...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

...NDA for the OX1R/OX2R dual antagonist by year-end. Boehringer joins other MNCs with China center Boehringer Ingelheim GmbH...
...three of the pharma’s programs -- Research Beyond Borders, Business Development & Licensing and the Boehringer Ingelheim...
...7 BioCentury Staff BLU-5937, neo5937 Linzagolix (KLH-2109, OBE2109) Cami-T, HuMax-TAC-ADC, camidanlumab tesirine (ADCT-301) daridorexant (ACT-541468) UCARTCS1 Bellus Health Inc. ObsEva S.A. ADC Therapeutics S.A. Idorsia Ltd. Boehringer Ingelheim GmbH Cellectis...
Items per page:
1 - 10 of 2326
BioCentury | Sep 20, 2020
Product Development

Amgen highlights durability, seeks biomarkers as response rates slip for KRAS inhibitor AMG 510

...in combination with a pan-KRAS inhibitor from Boehringer Ingelheim GmbH...
BioCentury | Sep 17, 2020
Deals

Mirati and Boehringer partner to test KRAS-KRAS combo

...G12C mutation-selective inhibitor MRTX849 from Mirati Therapeutics Inc. (NASDAQ:MRTX) in combination with BI 1701963, a SOS1:pan-KRAS inhibitor from Boehringer Ingelheim GmBH...
...Src homology protein tyrosine phosphatase 2SOS1 – Sons of sevenless homolog 1 Lauren Martz Mirati Therapeutics Inc. Amgen Inc. Boehringer Ingelheim GmbH KRAS...
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...point to therapeutic targets. Companies involved include Boehringer Ingelheim GmbH...
BioCentury | Sep 10, 2020
Finance

MiNA raises £23M in first venture round 12 years after launch

...for metabolic diseases, and is developing saRNA candidates for fibrotic diseases, including non-alcoholic steatohepatitis (NASH), with Boehringer Ingelheim GmbH...
BioCentury | Aug 22, 2020
Product Development

Europe’s five-year plan to tackle COVID-19 and other coronavirus threats

...best possible compound much faster.” Cyrille Kuhn, Boehringer Ingelheim...
...antibody discovery through development to viable therapies.For example,  Boehringer Ingelheim GmbH is...
...Co. Ltd. European Federation of Pharmaceutical Industries and Associations Boehringer Ingelheim Bill...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...and develop biomarkers for the early detection of cardiovascular disease. The round was led by Boehringer Ingelheim...
BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

...Medicine in 2018 with €8 million in seed funding from founding investors Andera Partners and Boehringer Ingelheim...
...of employees: 18 Funds raised: €74 million Investors: Versant Ventures, RA Capital Management, Andera Partners, Boehringer Ingelheim...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...countries (see “ Atogepant Phase IIb/III to Prevent Migraine ”). Jardiance reduces heart failure risk Boehringer Ingelheim GmbH...
...G12C inhibitor-unknown MRTX849 sotorasib (AMG 510) Keytruda, pembrolizumab (MK-3475, lambrolizumab) ravidasvir (ASC16, PPI-668) Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) AL001 Boehringer Ingelheim GmbH AbbVie...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...raises seed funding from BI, Evotec Quantro Therapeutics GmbH raised an undisclosed seed round from Boehringer Ingelheim GmbH...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

...NDA for the OX1R/OX2R dual antagonist by year-end. Boehringer joins other MNCs with China center Boehringer Ingelheim GmbH...
...three of the pharma’s programs -- Research Beyond Borders, Business Development & Licensing and the Boehringer Ingelheim...
...7 BioCentury Staff BLU-5937, neo5937 Linzagolix (KLH-2109, OBE2109) Cami-T, HuMax-TAC-ADC, camidanlumab tesirine (ADCT-301) daridorexant (ACT-541468) UCARTCS1 Bellus Health Inc. ObsEva S.A. ADC Therapeutics S.A. Idorsia Ltd. Boehringer Ingelheim GmbH Cellectis...
Items per page:
1 - 10 of 2326